Key Insights
The US Diabetes Drugs and Devices Market is poised for significant expansion, projected to reach $60.12 million by 2025, with a robust Compound Annual Growth Rate (CAGR) exceeding 4.00% throughout the forecast period of 2025-2033. This growth is primarily fueled by a confluence of factors, including the escalating prevalence of diabetes across all demographics, advancements in drug development for more effective glycemic control, and the rapid innovation in diabetes management devices. The increasing adoption of continuous glucose monitoring (CGM) systems and insulin pumps signifies a paradigm shift towards more personalized and proactive diabetes care. Furthermore, a growing awareness among patients and healthcare providers regarding the long-term complications of uncontrolled diabetes is driving the demand for comprehensive treatment solutions. Government initiatives aimed at improving diabetes care access and affordability are also contributing to market buoyancy.
US Diabetes Drugs and Devices Market Market Size (In Million)
The market is segmented into distinct categories: Devices, encompassing both monitoring (self-monitoring blood glucose meters and CGMs) and management solutions (insulin pumps, syringes, cartridges, and disposable pens), and Drugs, which include oral anti-diabetic medications, various forms of insulin, combination therapies, and non-insulin injectable drugs. Key players like Roche, Abbott, Medtronic, Dexcom, Novo Nordisk, and Eli Lilly are at the forefront of this innovation, continuously introducing advanced products and therapies. While the market exhibits strong growth potential, certain restraints, such as the high cost of advanced devices and novel drug therapies, and reimbursement challenges, may pose hurdles. However, the increasing focus on preventative care and the growing demand for integrated diabetes management solutions are expected to outweigh these challenges, ensuring sustained market momentum in the coming years.
US Diabetes Drugs and Devices Market Company Market Share
This report offers an in-depth examination of the US Diabetes Drugs and Devices Market, a critical and rapidly evolving sector within the healthcare industry. With a focus on the period from 2019 to 2033, including a base year of 2025 and a forecast period from 2025 to 2033, this analysis provides actionable insights for stakeholders. The US diabetes market is characterized by increasing prevalence of diabetes, advancements in therapeutic and monitoring technologies, and significant investment in research and development. This report delves into the intricate dynamics of this market, covering key segments, dominant players, and future trends.
US Diabetes Drugs and Devices Market Market Concentration & Innovation
The US Diabetes Drugs and Devices Market exhibits a moderate to high level of concentration, with a few dominant companies holding significant market share. Innovation is a primary driver of growth, fueled by substantial R&D investments from leading pharmaceutical and medical device manufacturers. Key innovation areas include the development of novel drug classes, advanced insulin delivery systems, and sophisticated continuous glucose monitoring (CGM) technologies. The regulatory landscape, overseen by the U.S. Food and Drug Administration (FDA), plays a crucial role in shaping product approvals and market access.
- Market Concentration: Dominated by key players such as Novo Nordisk, Eli Lilly, Sanofi, Abbott, Dexcom, and Medtronic.
- Innovation Drivers: Development of next-generation insulins, oral anti-diabetic agents, advanced CGM sensors, smart insulin pens, and closed-loop insulin delivery systems.
- Regulatory Frameworks: FDA approvals for new drugs and devices, post-market surveillance, and stringent quality control measures.
- Product Substitutes: While direct substitutes are limited, lifestyle modifications and emerging alternative therapies are considered indirect competitors.
- End-User Trends: Growing demand for user-friendly, integrated diabetes management solutions, remote patient monitoring capabilities, and personalized treatment approaches.
- M&A Activities: Strategic acquisitions and partnerships aimed at expanding product portfolios, gaining access to new technologies, and consolidating market presence. Deal values in recent years have been in the hundreds of millions to billions of dollars.
US Diabetes Drugs and Devices Market Industry Trends & Insights
The US Diabetes Drugs and Devices Market is poised for significant expansion, driven by a confluence of escalating diabetes prevalence, technological advancements, and evolving patient expectations. The aging population, coupled with sedentary lifestyles and dietary changes, continues to fuel the incidence of both type 1 and type 2 diabetes, creating a sustained demand for effective treatments and management tools. Technological innovations are transforming diabetes care, moving towards more integrated and personalized solutions. Continuous Glucose Monitoring (CGM) devices are rapidly gaining traction, offering real-time glucose data and reducing the need for frequent finger pricks, thereby improving patient adherence and glycemic control. Similarly, advancements in insulin pump technology, including the development of automated insulin delivery systems and smart pens, are enhancing the precision and convenience of insulin therapy.
The competitive landscape is dynamic, with established players continuously innovating and newer entrants challenging the status quo with disruptive technologies. Pharmaceutical companies are investing heavily in the development of novel oral anti-diabetic drugs and advanced insulin formulations, while medical device manufacturers are focusing on miniaturization, connectivity, and data analytics for their devices. The rise of digital health platforms and telemedicine is further influencing the market by enabling remote patient monitoring and personalized coaching, thereby fostering a more proactive approach to diabetes management. Consumer preferences are shifting towards solutions that offer greater convenience, accuracy, and integration with other health tracking devices. The market penetration of advanced diabetes management technologies is expected to increase significantly as these solutions become more accessible and cost-effective. The Compound Annual Growth Rate (CAGR) for the US Diabetes Drugs and Devices Market is projected to be robust, estimated between 6% and 9% over the forecast period, reflecting the strong underlying demand and innovation.
Dominant Markets & Segments in US Diabetes Drugs and Devices Market
The US Diabetes Drugs and Devices Market is segmented into both drugs and devices, with specific sub-segments demonstrating significant market dominance. Within the devices segment, Monitoring Devices hold a substantial share, primarily driven by the escalating adoption of Continuous Blood Glucose Monitoring (CGM) systems. These advanced devices offer real-time glucose readings, trend analysis, and alerts, empowering individuals with diabetes to make more informed management decisions. The shift from traditional Self-monitoring Blood Glucose Devices to CGM is a key trend, facilitated by technological improvements in sensor accuracy, wearability, and data connectivity.
In the Management Devices category, Insulin Pumps represent a significant market segment. These devices deliver a continuous supply of rapid-acting insulin, mimicking the function of a healthy pancreas and offering a more sophisticated alternative to multiple daily injections. The market for insulin pumps is further segmented by type, including tubed and tubeless (patch) pumps, with the latter gaining popularity due to their discreet nature and ease of use. Insulin Syringes, Insulin Cartridges, and Disposable Pens remain essential components of diabetes management, catering to a broad patient population, particularly those who prefer or require traditional injection methods.
On the drugs side, Insulin Drugs constitute a cornerstone of diabetes treatment, essential for individuals with type 1 diabetes and many with type 2 diabetes. The market is characterized by various formulations, including rapid-acting, short-acting, intermediate-acting, and long-acting insulins. Oral Anti-Diabetes Drugs, particularly Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors and Dipeptidyl Peptidase-4 (DPP-4) inhibitors, have also witnessed substantial growth, offering effective glycemic control for type 2 diabetes patients with improved safety profiles. Combination Drugs, which combine multiple active ingredients to target different aspects of glucose regulation, are increasingly being utilized to achieve optimal therapeutic outcomes. Non-Insulin Injectable Drugs, such as Glucagon-Like Peptide-1 (GLP-1) receptor agonists, have emerged as powerful therapeutic options, offering not only glycemic control but also weight management and cardiovascular benefits, driving significant growth within this segment.
- Dominant Segments:
- Devices:
- Monitoring Devices: Continuous Blood Glucose Monitoring (CGM)
- Management Devices: Insulin Pumps
- Drugs:
- Insulin Drugs
- Non-Insulin Injectable Drugs (e.g., GLP-1 RAs)
- Devices:
- Key Drivers for Dominance:
- Technological Advancements: Improved accuracy, usability, and connectivity of CGM and insulin pump systems.
- Evolving Treatment Paradigms: Shift towards comprehensive diabetes management strategies that integrate monitoring and delivery devices.
- Clinical Efficacy: Demonstrated benefits of new drug classes in improving glycemic control, reducing complications, and managing comorbidities.
- Patient Preferences: Demand for convenient, discreet, and user-friendly solutions.
- Reimbursement Policies: Favorable coverage for advanced diabetes technologies and medications.
- Awareness and Education: Increased patient and physician awareness of the benefits of modern diabetes management tools and therapies.
US Diabetes Drugs and Devices Market Product Developments
The US Diabetes Drugs and Devices Market is consistently shaped by groundbreaking product developments. Recent innovations include the FDA approval of Lantidra, the first allogeneic pancreatic islet cellular therapy, offering a new avenue for type 1 diabetes management in specific patient populations. Furthermore, the approval of Bexagliflozin (Brenzavvy) as an oral SGLT2 inhibitor for type 2 diabetes underscores the ongoing development of effective oral anti-diabetic agents. These advancements reflect a strong trend towards more targeted therapies and innovative treatment modalities, enhancing patient outcomes and quality of life.
Report Scope & Segmentation Analysis
This report meticulously segments the US Diabetes Drugs and Devices Market into its core components. The Devices segment encompasses Monitoring Devices, further broken down into Self-monitoring Blood Glucose Devices and Continuous Blood Glucose Monitoring (CGM). The Management Devices sub-segment includes Insulin Pumps, Insulin Syringes, Insulin Cartridges, and Disposable Pens. The Drugs segment is analyzed across Oral Anti-Diabetes Drugs, Insulin Drugs, Combination Drugs, and Non-Insulin Injectable Drugs. Each segment is assessed for its current market size, projected growth, and competitive dynamics, providing a granular understanding of the market landscape. Growth projections indicate strong expansion across advanced monitoring and delivery devices, as well as novel drug classes.
Key Drivers of US Diabetes Drugs and Devices Market Growth
The growth of the US Diabetes Drugs and Devices Market is propelled by several interconnected factors. The escalating prevalence of diabetes, attributed to demographic shifts and lifestyle changes, creates a sustained and growing demand for both therapeutic and management solutions. Technological innovation is a significant catalyst, with advancements in Continuous Glucose Monitoring (CGM) and automated insulin delivery systems revolutionizing diabetes care. Furthermore, a supportive regulatory environment that facilitates the approval of novel drugs and devices, coupled with increasing reimbursement for these technologies, plays a crucial role. Increased patient and healthcare provider awareness regarding the benefits of advanced diabetes management strategies further fuels market expansion.
Challenges in the US Diabetes Drugs and Devices Market Sector
Despite robust growth, the US Diabetes Drugs and Devices Market faces several challenges. High treatment costs associated with advanced devices and newer drug therapies can present a barrier to widespread access and affordability for some patient populations. Stringent regulatory approval processes, while essential for safety, can also lead to extended development timelines for new products. Supply chain disruptions, as witnessed in recent global events, can impact the availability of critical components and finished goods. Moreover, intense competition among established players and emerging innovators necessitates continuous investment in R&D to maintain market share, which can strain resources for smaller companies.
Emerging Opportunities in US Diabetes Drugs and Devices Market
Emerging opportunities within the US Diabetes Drugs and Devices Market are abundant and diverse. The increasing focus on personalized medicine presents a significant opportunity for tailored drug therapies and device functionalities based on individual patient profiles. The expansion of digital health platforms and telemedicine enables enhanced remote patient monitoring and virtual care, improving accessibility and patient engagement. The development of smart insulin pens and integrated systems that seamlessly connect various diabetes management tools offers greater convenience and data integration. Furthermore, the growing recognition of the impact of diabetes on cardiovascular health is driving the development and adoption of therapies that offer dual benefits, such as glycemic control and cardiovascular risk reduction.
Leading Players in the US Diabetes Drugs and Devices Market Market
- Roche
- Ypsomed
- Pfizer
- Abbott
- AstraZeneca
- Eli Lilly
- Sanofi
- Novartis
- Medtronic
- Tandem
- Insulet
- Novo Nordisk
- Dexcom
Key Developments in US Diabetes Drugs and Devices Market Industry
- June 2023: Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy, received FDA approval for the management of type 1 diabetes in adults with recurrent severe hypoglycemia.
- January 2023: Bexagliflozin (Brenzavvy), an oral SGLT2 inhibitor, was approved by the FDA for the management of type 2 diabetes in adults, as an adjunct to diet and exercise.
Strategic Outlook for US Diabetes Drugs and Devices Market Market
The strategic outlook for the US Diabetes Drugs and Devices Market is characterized by continued innovation and market expansion. Growth catalysts include the ongoing development of novel therapeutic agents, particularly for type 2 diabetes, and the increasing sophistication of diabetes management devices, such as advanced insulin pumps and CGM systems that offer greater automation and connectivity. The integration of artificial intelligence and machine learning in diabetes care, for predictive analytics and personalized treatment recommendations, presents a significant future growth avenue. Furthermore, a growing emphasis on preventative care and early intervention strategies will likely drive demand for accessible and user-friendly diabetes management solutions, solidifying the market's strong growth trajectory.
US Diabetes Drugs and Devices Market Segmentation
-
1. Devices
-
1.1. Monitoring Devices
- 1.1.1. Self-monitoring Blood Glucose Devices
- 1.1.2. Continuous Blood Glucose Monitoring
-
1.2. Management Devices
- 1.2.1. Insulin Pump
- 1.2.2. Insulin Syringes
- 1.2.3. Insulin Cartridges
- 1.2.4. Disposable Pens
-
1.1. Monitoring Devices
-
2. Drugs
- 2.1. Oral Anti-Diabetes Drugs
- 2.2. Insulin Drugs
- 2.3. Combination Drugs
- 2.4. Non-Insulin Injectable Drugs
US Diabetes Drugs and Devices Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
-
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
-
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
-
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific
US Diabetes Drugs and Devices Market Regional Market Share
Geographic Coverage of US Diabetes Drugs and Devices Market
US Diabetes Drugs and Devices Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of > 4.00% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. ; The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies
- 3.3. Market Restrains
- 3.3.1 ; Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures
- 3.3.2 Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products
- 3.4. Market Trends
- 3.4.1. Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. US Diabetes Drugs and Devices Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Devices
- 5.1.1. Monitoring Devices
- 5.1.1.1. Self-monitoring Blood Glucose Devices
- 5.1.1.2. Continuous Blood Glucose Monitoring
- 5.1.2. Management Devices
- 5.1.2.1. Insulin Pump
- 5.1.2.2. Insulin Syringes
- 5.1.2.3. Insulin Cartridges
- 5.1.2.4. Disposable Pens
- 5.1.1. Monitoring Devices
- 5.2. Market Analysis, Insights and Forecast - by Drugs
- 5.2.1. Oral Anti-Diabetes Drugs
- 5.2.2. Insulin Drugs
- 5.2.3. Combination Drugs
- 5.2.4. Non-Insulin Injectable Drugs
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. South America
- 5.3.3. Europe
- 5.3.4. Middle East & Africa
- 5.3.5. Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Devices
- 6. North America US Diabetes Drugs and Devices Market Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Devices
- 6.1.1. Monitoring Devices
- 6.1.1.1. Self-monitoring Blood Glucose Devices
- 6.1.1.2. Continuous Blood Glucose Monitoring
- 6.1.2. Management Devices
- 6.1.2.1. Insulin Pump
- 6.1.2.2. Insulin Syringes
- 6.1.2.3. Insulin Cartridges
- 6.1.2.4. Disposable Pens
- 6.1.1. Monitoring Devices
- 6.2. Market Analysis, Insights and Forecast - by Drugs
- 6.2.1. Oral Anti-Diabetes Drugs
- 6.2.2. Insulin Drugs
- 6.2.3. Combination Drugs
- 6.2.4. Non-Insulin Injectable Drugs
- 6.1. Market Analysis, Insights and Forecast - by Devices
- 7. South America US Diabetes Drugs and Devices Market Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Devices
- 7.1.1. Monitoring Devices
- 7.1.1.1. Self-monitoring Blood Glucose Devices
- 7.1.1.2. Continuous Blood Glucose Monitoring
- 7.1.2. Management Devices
- 7.1.2.1. Insulin Pump
- 7.1.2.2. Insulin Syringes
- 7.1.2.3. Insulin Cartridges
- 7.1.2.4. Disposable Pens
- 7.1.1. Monitoring Devices
- 7.2. Market Analysis, Insights and Forecast - by Drugs
- 7.2.1. Oral Anti-Diabetes Drugs
- 7.2.2. Insulin Drugs
- 7.2.3. Combination Drugs
- 7.2.4. Non-Insulin Injectable Drugs
- 7.1. Market Analysis, Insights and Forecast - by Devices
- 8. Europe US Diabetes Drugs and Devices Market Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Devices
- 8.1.1. Monitoring Devices
- 8.1.1.1. Self-monitoring Blood Glucose Devices
- 8.1.1.2. Continuous Blood Glucose Monitoring
- 8.1.2. Management Devices
- 8.1.2.1. Insulin Pump
- 8.1.2.2. Insulin Syringes
- 8.1.2.3. Insulin Cartridges
- 8.1.2.4. Disposable Pens
- 8.1.1. Monitoring Devices
- 8.2. Market Analysis, Insights and Forecast - by Drugs
- 8.2.1. Oral Anti-Diabetes Drugs
- 8.2.2. Insulin Drugs
- 8.2.3. Combination Drugs
- 8.2.4. Non-Insulin Injectable Drugs
- 8.1. Market Analysis, Insights and Forecast - by Devices
- 9. Middle East & Africa US Diabetes Drugs and Devices Market Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Devices
- 9.1.1. Monitoring Devices
- 9.1.1.1. Self-monitoring Blood Glucose Devices
- 9.1.1.2. Continuous Blood Glucose Monitoring
- 9.1.2. Management Devices
- 9.1.2.1. Insulin Pump
- 9.1.2.2. Insulin Syringes
- 9.1.2.3. Insulin Cartridges
- 9.1.2.4. Disposable Pens
- 9.1.1. Monitoring Devices
- 9.2. Market Analysis, Insights and Forecast - by Drugs
- 9.2.1. Oral Anti-Diabetes Drugs
- 9.2.2. Insulin Drugs
- 9.2.3. Combination Drugs
- 9.2.4. Non-Insulin Injectable Drugs
- 9.1. Market Analysis, Insights and Forecast - by Devices
- 10. Asia Pacific US Diabetes Drugs and Devices Market Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Devices
- 10.1.1. Monitoring Devices
- 10.1.1.1. Self-monitoring Blood Glucose Devices
- 10.1.1.2. Continuous Blood Glucose Monitoring
- 10.1.2. Management Devices
- 10.1.2.1. Insulin Pump
- 10.1.2.2. Insulin Syringes
- 10.1.2.3. Insulin Cartridges
- 10.1.2.4. Disposable Pens
- 10.1.1. Monitoring Devices
- 10.2. Market Analysis, Insights and Forecast - by Drugs
- 10.2.1. Oral Anti-Diabetes Drugs
- 10.2.2. Insulin Drugs
- 10.2.3. Combination Drugs
- 10.2.4. Non-Insulin Injectable Drugs
- 10.1. Market Analysis, Insights and Forecast - by Devices
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Roche
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Ypsomed
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Pfizer
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Abbottt
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Astrazeneca
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Eli Lilly
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Sanofi
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Novartis
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Medtronic
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Tandem
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Insulet
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 Novo Nordisk
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.13 Dexcom
- 11.2.13.1. Overview
- 11.2.13.2. Products
- 11.2.13.3. SWOT Analysis
- 11.2.13.4. Recent Developments
- 11.2.13.5. Financials (Based on Availability)
- 11.2.1 Roche
List of Figures
- Figure 1: US Diabetes Drugs and Devices Market Revenue Breakdown (Million, %) by Product 2025 & 2033
- Figure 2: US Diabetes Drugs and Devices Market Share (%) by Company 2025
List of Tables
- Table 1: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Devices 2020 & 2033
- Table 2: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Devices 2020 & 2033
- Table 3: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Drugs 2020 & 2033
- Table 4: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Drugs 2020 & 2033
- Table 5: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Region 2020 & 2033
- Table 6: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Region 2020 & 2033
- Table 7: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Devices 2020 & 2033
- Table 8: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Devices 2020 & 2033
- Table 9: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Drugs 2020 & 2033
- Table 10: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Drugs 2020 & 2033
- Table 11: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Country 2020 & 2033
- Table 12: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 13: United States US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 14: United States US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 15: Canada US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 16: Canada US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 17: Mexico US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 18: Mexico US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 19: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Devices 2020 & 2033
- Table 20: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Devices 2020 & 2033
- Table 21: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Drugs 2020 & 2033
- Table 22: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Drugs 2020 & 2033
- Table 23: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Country 2020 & 2033
- Table 24: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 25: Brazil US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 26: Brazil US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 27: Argentina US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 28: Argentina US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 29: Rest of South America US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 30: Rest of South America US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 31: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Devices 2020 & 2033
- Table 32: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Devices 2020 & 2033
- Table 33: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Drugs 2020 & 2033
- Table 34: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Drugs 2020 & 2033
- Table 35: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Country 2020 & 2033
- Table 36: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 37: United Kingdom US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 38: United Kingdom US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 39: Germany US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 40: Germany US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 41: France US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 42: France US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 43: Italy US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 44: Italy US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 45: Spain US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 46: Spain US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 47: Russia US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 48: Russia US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 49: Benelux US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 50: Benelux US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 51: Nordics US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 52: Nordics US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 53: Rest of Europe US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 54: Rest of Europe US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 55: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Devices 2020 & 2033
- Table 56: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Devices 2020 & 2033
- Table 57: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Drugs 2020 & 2033
- Table 58: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Drugs 2020 & 2033
- Table 59: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Country 2020 & 2033
- Table 60: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 61: Turkey US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 62: Turkey US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 63: Israel US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 64: Israel US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 65: GCC US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 66: GCC US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 67: North Africa US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 68: North Africa US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 69: South Africa US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 70: South Africa US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 71: Rest of Middle East & Africa US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 72: Rest of Middle East & Africa US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 73: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Devices 2020 & 2033
- Table 74: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Devices 2020 & 2033
- Table 75: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Drugs 2020 & 2033
- Table 76: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Drugs 2020 & 2033
- Table 77: US Diabetes Drugs and Devices Market Revenue Million Forecast, by Country 2020 & 2033
- Table 78: US Diabetes Drugs and Devices Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 79: China US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 80: China US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 81: India US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 82: India US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 83: Japan US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 84: Japan US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 85: South Korea US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 86: South Korea US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 87: ASEAN US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 88: ASEAN US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 89: Oceania US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 90: Oceania US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 91: Rest of Asia Pacific US Diabetes Drugs and Devices Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 92: Rest of Asia Pacific US Diabetes Drugs and Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the US Diabetes Drugs and Devices Market?
The projected CAGR is approximately > 4.00%.
2. Which companies are prominent players in the US Diabetes Drugs and Devices Market?
Key companies in the market include Roche, Ypsomed, Pfizer, Abbottt, Astrazeneca, Eli Lilly, Sanofi, Novartis, Medtronic, Tandem, Insulet, Novo Nordisk, Dexcom.
3. What are the main segments of the US Diabetes Drugs and Devices Market?
The market segments include Devices, Drugs.
4. Can you provide details about the market size?
The market size is estimated to be USD 60.12 Million as of 2022.
5. What are some drivers contributing to market growth?
; The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies.
6. What are the notable trends driving market growth?
Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period.
7. Are there any restraints impacting market growth?
; Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures. Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products.
8. Can you provide examples of recent developments in the market?
June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells, Lantidra, has been sanctioned by the U.S. Food and Drug Administration for the management of type 1 diabetes. Lantidra is specifically authorized for adults with type 1 diabetes who are incapable of achieving target glycated hemoglobin (average blood glucose levels) due to recurrent episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3800, USD 4500, and USD 5800 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "US Diabetes Drugs and Devices Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the US Diabetes Drugs and Devices Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the US Diabetes Drugs and Devices Market?
To stay informed about further developments, trends, and reports in the US Diabetes Drugs and Devices Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence